• Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
Tech News, Magazine & Review WordPress Theme 2017
  • Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
No Result
View All Result
  • Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
No Result
View All Result
Blog - Creative Collaboration
No Result
View All Result
Home Sci-Fi

Anterior grabs $20M from NEA to expedite health insurance approvals with AI

June 8, 2024
Share on FacebookShare on Twitter

Anterior, a company that uses AI to expedite health insurance approval for medical procedures, has raised a $20 million Series A round at a $95 million post-money valuation led by NEA, according to two people familiar with the deal. Existing investors Sequoia, which led Anterior’s $3.2 million seed round last September, and Neo, an accelerator that helped the company launch in the summer of 2022, also participated in the Series A financing.

The round also included a host of angel investors, including Mustafa Suleyman, a DeepMind and Inflection AI co-founder who was hired by Microsoft in March to lead the tech giant’s consumer AI division.

NEA and Anterior didn’t immediately respond to a request for comment.

Anterior, formerly known as Co:helm, was co-founded by Abdel Mahmoud, a former doctor who left medicine to pursue a master’s degree in computer science and a career in tech after he grew frustrated with the amount of time he spent on administrative functions rather than with patience.   

The company has built an LLM-powered co-pilot that helps nurses and doctors save hours on gathering medical documentation required by insurance. Anterior’s solution aims to reduce denial rates and accelerate patient access to care.

While Anterior’s initial offering is in prior authorization automation, the company eventually plans to expand into other medical administrative functions.

Mohamad Makhzoumi, managing general partner on NEA’s healthcare team and co-CEO of the firm, joined Anterior’s board. Makhzoumi’s investments include Tempus, a genomic testing and data analysis company founded by Groupon founder Eric Lefkofsky, which is planning to IPO next week at a valuation of up to $6.1 billion. Makhzoimi also backed Xaira, an AI drug discovery startup that launched this year with $1 billion in funding.

Anterior competes with Cohere Health, another provider of prior authorization automation, which raised a $50 million round in February led by Deerfield Management, with participation from Define Ventures, Flare Capital Partners, Longitude Capital and Polaris Partners, bringing the five-year-old company’s total funding to $106 million.  

Next Post

iPhone 16 battery leaks, might not overheat like on iPhone 15

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

No Result
View All Result

Recent Posts

  • MWC 2026: AI, foldables, satellite connectivity, and memory crisis
  • USB-C fast charging is still a nightmare, but this phone finally gets it right
  • Yakuza Kiwami 3 & Dark Ties Review – Twisted Voxel
  • I stopped using this Google app years ago until a surprise update changed everything
  • Amazon has a 39-inch LG Ultragear Curved Gaming Monitor on sale for 45% off

Recent Comments

    No Result
    View All Result

    Categories

    • Android
    • Cars
    • Gadgets
    • Gaming
    • Internet
    • Mobile
    • Sci-Fi
    • Home
    • Shop
    • Privacy Policy
    • Terms and Conditions

    © CC Startup, Powered by Creative Collaboration. © 2020 Creative Collaboration, LLC. All Rights Reserved.

    No Result
    View All Result
    • Home
    • Blog
    • Android
    • Cars
    • Gadgets
    • Gaming
    • Internet
    • Mobile
    • Sci-Fi

    © CC Startup, Powered by Creative Collaboration. © 2020 Creative Collaboration, LLC. All Rights Reserved.

    Get more stuff like this
    in your inbox

    Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

    Thank you for subscribing.

    Something went wrong.

    We respect your privacy and take protecting it seriously